… deeper understanding of the molecular basis and mechanisms of action of antitumor agents
to clinically manage adverse events. Considering different clinical observations and current …

… molecular targets discussed in this Review are still in clinical or preclinical stages of
development. If trials are successful, clinicians … pain relief that is free from debilitating side effects. …

… GC resistance in RA is not well defined; for daily practice waning of symptomatic relief is
considered to be a sign of GC resistance. By this definition, over 30% of patients with RA …

Although treatment of one unusually aggressive case of postmenopausal endometriosis
with an aromatase inhibitor has been strikingly successful, large clinical trials are required to …

… Patients who expect pain relief and know how to request it....are more likely to have … relief.
With the time taken to evaluate NSAIDs and opioids, patients who finally achieve pain relief …

Acute‐on‐chronic liver failure (ACLF) is a frequent cause of death in cirrhosis. Albumin
dialysis with the molecular adsorbent recirculating system (MARS) decreases retained …

… Previous cholinergic drugs only offered symptomatic relief from Alzheimer’s disease, while
memantine is believed to be the first neuroprotective drug to achieve clinical approval. The …

… Although the molecular basis of HD is known, there is no known cure for this disease other
than symptomatic relief treatment approaches. The toxicity of mutHTT appears to be more …

… Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res 37:3483–3493, …
Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nature …

… , many clinical trials have demonstrated that cisplatin-based chemotherapy not only improves
survival rates significantly in patients with NSCLC, but also provides symptom relief (5,19). …